# MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer

> **NCT01263145** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Adult Solid Neoplasm
- Recurrent Breast Carcinoma
- Stage IV Breast Cancer

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01263145
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-05
- **Primary completion:** 2012-10-19
- **Final completion:** 2012-10-19
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263145, "MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01263145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*